Literature DB >> 8569199

The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates.

T Murata1, K Nakagawa, A Khalil, T Ishibashi, H Inomata, K Sueishi.   

Abstract

Vascular endothelial growth factor (VEGF) has been identified as an endothelial cell-specific mitogen with potent angiogenic properties. VEGF is overexpressed in pathologic angiogenesis observed in tumor growth, rheumatoid arthritis, and retinal angiogenic diseases such as diabetic retinopathy and retinopathy of prematurity. VEGF expression in physiologic angiogenesis, i.e., vasculogenesis, has also been reported in the embryonic organs such as brain, kidney, spleen, and lung. However, the details of VEGF expression in vasculogenesis remain largely unclear. To determine if VEGF contributes to vasculogenesis in the developing tissues, VEGF expression was studied by both immunohistochemistry and in situ hybridization in newborn rat retinas on postnatal days 3, 7, 14, and 30. Vasculogenesis was assessed by both the ink perfusion method and a histologic examination. To identify the cell types of VEGF-expressing cells, immunohistochemistry for cell markers such as glial fibrillary acidic protein and von Willebrand factor was performed. On postnatal days 3 and 7, when retinal vasculogenesis was active, VEGF mRNA and protein(s) were prominently expressed in the ganglion cell and the inner nuclear layers. In rats, as well as humans, these two layers are where the retinal vessels develop, and these two layers depend solely on the retinal vessels. In addition to the ganglion and the inner nuclear layers, VEGF protein(s) were located in the endothelial cells of the developing vessels and the angioblasts, i.e., endothelial precursors. On postnatal day 14, when vasculogenesis became inactive, VEGF mRNA expression markedly decreased. These results indicated that VEGF expression in the developing retinas is temporally and spatially correlated with retinal vasculogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8569199

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  Meta analysis on the relationship between gene polymorphisms of vascular endothelial growth factor and retinal prognosis risk of prematurity.

Authors:  Jun Zhai; Qiu-Hui Jiang; Chun-Xi Liu; Zuo-Rong Tian; Ying-Pu Sun
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

Review 3.  Vascular endothelial growth factor biology: clinical implications for ocular treatments.

Authors:  R B Bhisitkul
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

Review 4.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

5.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

6.  Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy.

Authors:  G Smith; D McLeod; D Foreman; M Boulton
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

Review 7.  Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.

Authors:  Aniruddha Amrite; Vidya Pugazhenthi; Narayan Cheruvu; Uday Kompella
Journal:  Expert Opin Drug Deliv       Date:  2010-05       Impact factor: 6.648

8.  Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.

Authors:  K Lashkari; T Hirose; J Yazdany; J W McMeel; A Kazlauskas; N Rahimi
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

9.  Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.

Authors:  Eun Jee Chung; Ji Hyun Kim; Hyun Seok Ahn; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-10       Impact factor: 3.117

10.  Targeting VEGF in canine oxygen-induced retinopathy - a model for human retinopathy of prematurity.

Authors:  D Scott McLeod; Gerard A Lutty
Journal:  Eye Brain       Date:  2016-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.